Table 1. Baseline characteristics of the included trials.
Rego 80+ is a dose‐escalation strategy with weekly increase in the dosing if no drug‐related side effects up to 160 mg/day.
Abbreviations: BSC, best‐supportive care and placebo; ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression‐free survival; PS, performance status.